Avelox (Moxifloxacin, BAY12-8039)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Maxillary Sinusitis
Conditions
Maxillary Sinusitis
Trial Timeline
Jun 1, 2004 → Jan 1, 2005
NCT ID
NCT00668304About Avelox (Moxifloxacin, BAY12-8039)
Avelox (Moxifloxacin, BAY12-8039) is a approved stage product being developed by Bayer for Maxillary Sinusitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00668304. Target conditions include Maxillary Sinusitis.
What happened to similar drugs?
1 of 4 similar drugs in Maxillary Sinusitis were approved
Approved (1) Terminated (1) Active (3)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01690533 | Pre-clinical | Completed |
| NCT00930488 | Pre-clinical | Completed |
| NCT00668304 | Approved | Completed |
Competing Products
5 competing products in Maxillary Sinusitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| levofloxacin | Johnson & Johnson | Phase 3 | 40 |
| Azithromycin SR + Amoxiclav 1000 mg | Pfizer | Pre-clinical | 26 |
| azithromycin SR (Zithromax; compound: CP-62,993) + levofloxacin | Pfizer | Phase 3 | 40 |
| Telithromycin | Sanofi | Phase 3 | 40 |
| Azithromycin + Telithromycin | Sanofi | Approved | 35 |